as per attachment

Revenue Growth 20pctEbitda Margin CompressionResults View source PDF Explain this filing

VAISHALI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.4%Reaction day

₹12.38

prior close

₹12.41

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-1.4% vs market

Pharmaceuticals peers, median of 151sector+0.0%-1.4% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.2

15m

-0.4

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.4+0.0-1.4+0.0-1.4

Next day

-1.6+0.7-2.3+0.1-1.7

-0.6-0.1-0.5-0.1-0.5

-0.3+1.4-1.7+0.5-0.8

+1.0+2.6-1.6+0.3+0.7

+1.4+2.5-1.2+0.4+1.0

-1.2+2.2-3.4+1.0-2.2

15d

-2.4+1.9-4.4-0.4-2.0

-3.5+2.8-6.3+1.7-5.2

-11.2+1.2-12.4-1.6-9.6

-21.7+2.2-23.9-3.2-18.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vaishali Pharma's board approved its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results, which received an unqualified limited review report from statutory auditor Raman S. Shah & Associates. Revenue from operations rose to ₹2,374.71 lakhs, up about 31% from ₹1,807.98 lakhs in the same quarter last year. However, profit after tax fell to ₹127.93 lakhs from ₹169.90 lakhs (down ~25%), and EPS dropped to ₹0.10 from ₹0.15, mainly due to higher purchase and other expenses. The board also approved the FY25 Annual Report and Director's Report, and fixed September 22, 2025 as the date for the 18th AGM, with the share transfer books closed from September 15-22, 2025.

Likely market impact

Top-line growth is healthy, but shrinking margins and a fall in profit may concern investors in the near term. The stock could see a mixed reaction as strong revenue is offset by weaker profitability.